Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension

Journal of Medicinal Food

Volumn 8, Issue 4, 2005, Pages 423-430

  Sano, Jun ^a   Ohki, Kohji ^a   Higuchi, Toshimasa ^a   Aihara, Kotaro ^a   Mizuno, Seiichi ^a   Kajimoto, Osami ^b   Nakagawa, Satoshi ^c   Kajimoto, Yoshitaka ^c   Nakamura, Yasunori ^a  

^a CALPIS Co Ltd   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Soiken Incorporation   (Japan)

Author keywords

Angiotensin I converting enzyme; Antihypertensive effect; Aspergillus oryzae protease; High normal blood pressure; Mild hypertension

Indexed keywords

CASEIN HYDROLYSATE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOLEUCYLPROLYLPROLINE; PEPTIDE; PLACEBO; PROTEINASE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASPERGILLUS ORYZAE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SYNTHESIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE;

ASPERGILLUS ORYZAE;

EID: 31044437013     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2005.8.423     Document Type: Article

References (40)

1. Eastern Stroke and Coronary Heart Disease Collaborative Research Group: Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 1998;352:1801-1807.
2. Macmahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002;360:1903-1913.
4. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-2446.
5. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183.
6. Appel LJ, Moore TJ, Obarzanek E, et al.: Clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-1124.
7. Skeggs LT, Kahn JE, Shumway NP: The preparation and function of the angiotensin-converting enzyme. J Exp Med 1956;103:295-299.
8. Maruyama S, Nakagomi K, Tomizuka N, Suzuki H: Angiotensin-converting enzyme inhibitor derived from an enzymatic hydrolysate of casein. II. Isolation and bradykinin-potentiating activity on the uterus and the ileum of rats. Agric Biol Chem 1985;49:1405-1409.
9. Ariyoshi Y: Angiotensin I-converting enzyme inhibitors derived from food proteins. Trends Food Sci Technol 1993;4:139-144.
10. Miyoshi S, Ishikawa H, Kaneko T, Fukui F, Tanaka H, Maruyama S: Structures and activity of angiotensin-converting enzyme inhibitors in an a-zein hydrolysate. Agric Biol Chem 1991;55:1313-1318.
11. Suetuna K: Blood pressure reduction and vasodialatory effects in vivo of peptides originating from sardine muscle. Clin Rep 1991;25:2245-2251.
12. Yokoyama K, Chiba H, Yoshikawa M: Peptides inhibitors for angiotensin I-converting enzyme from thermolysin digest of dried bonito. Biosci Biotechnol Biochem 1992;56:1541-1545.
13. Nakamura Y, Yamamoto N, Sakai K, Okubo S, Yamasaki S, Takano T: Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995;78:777-783.
14. Nakamura Y, Yamamoto N, Sakai K, Takano T: Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci 1995;78:1253-1257.
15. Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML: Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol 2001;52:745-754.
16. Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML: Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res 2002;69:103-111.
17. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T: A placebo-controlled study of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996;64:767-771.
18. Kajimoto O, Nakamura Y, Yada H, Moriguchi S, Hirata H, Takahashi F: Hypotensive effect of sour milk drink on mild and moderate hypertensive subjects [in Japanese]. J Jpn Soc Nutr Food Sci 2001;54:347-354.
19. Seppo L, Jauhiainen T, Poussa T, Korpela R: A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003;77:326-330.
20. Nakamura Y, Kajimoto O, Kaneko K, et al.: Effects of the liquid yogurts containing "lactotripeptide (VPP, IPP)" on high-normal blood pressure [in Japanese]. J Nutr Food 2004;7:123-137.
21. Mizuno S, Nishimura S, Matsuura K, Gotou T, Yamamoto N: Release of short and proline rich antihypertensive peptides from casein hydrolyzate with an Aspergillus oryzae protease. J Dairy Sci 2004;87:3183-3188.
22. Matsuura K, Mizuno S, Nishimura S, Gotou T, Yamamoto N: Quantitative analysis of antihypertensive peptides, Val-Pro-Pro and Ile-Pro-Pro, in casein hydrolyzate with Aspergillus oryzae protease by a LC-MS method. Milchwissenschaft 2005;60:24-27.
23. Mizuno S, Matsuura K, Gotou T, et al.: Antihypertensive effect of casein hydrolyzate with Aspergillus oryzae protease by a placebo-controlled clinical study for subjects with high-normal blood pressure and mild hypertension. Br J Nutr 2005;94:84-91.
24. Kawasaki T, Itoh K, Uezono K, Grimby G, Sasaki H: Estimation of 24-hour urinary sodium and potassium excretion from predicted value of 24-hour urinary creatinine excretion and fractional urine sodium/creatinine and potassium/creatinine ratio. In: Seventh Symposium on Salt, Vol. 2 (Kakihana H, Hardy HR Jr, Hoshi T, Toyokura K, eds.), Elsevier, New York, 1993, pp. 257-262.
25. Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in order persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998;279:839-846.
26. Eliot P: Observational studies of salt and blood pressure. Hypertension 1991;17(Suppl 1):I-3-I-8.
27. Cappuccio FP, MacGregor GA: Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens 1991;9:465-473.
28. Nakamura Y, Masuda O, Takano T: Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem 1996;60:488-489.
29. Masuda O, Nakamura Y, Takano T: Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 1996;126:3063-3067.
30. Satake M, Enjoh M, Nakamura Y, et al.: Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci Biotechnol Biochem 2002;66:378-384.
31. Fernandez PG, Galway AB, Kim BK: Prolonged normotention following cessation of therapy in uncomplicated essential hypertension. Clin Invest Med 1982;5:31-37.
32. Maland LJ, Lutz LJ, Castle CH: Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 1983;5:539-544.
33. Ohman P, Aurell M, Asplund J, et al.: A long-term follow-up of patients with essential hypertension treated with captopril. Acta Med Scand 1984;216:53-56.
34. Matsui T, Tamaya K, Seki E, Osajima K, Matsumoto K, Kawasaki T: Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin Exp Pharmacol Physiol 2002;29:204-208.
35. Tagawa K, Mizobe M, Noda K: A saturable tissue angiotensin I converting enzyme binding model for the pharmacokinetic analysis of Imidapril and its active metabolite in human. Biol Pharm Bull 1995;18:64-69.
36. Kim YS, Bertwhistle W, Kim YW: Peptide hydrolyses in the brush border and soluble fractions of small intestinal mucosa of rat and man. J Clin Invest 1972;51:1419-1430.
37. Adibi SA, Kim YS: Peptide absorption and hydrolysis. In: Physiology of the Gastrointestinal Tract (Johnson LR, ed.), Raven Press, New York, 1981, pp. 1097-1122.
38. Kawasaki T, Seki E, Osajima K, et al.: Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J Hum Hypertens 2000;14:519-523.
39. Fujita H, Yamagami T, Ohshima K: Effect of an ace-inhibitory agent, katsuobushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. Nutr Res 2001;21:1149-1158.
40. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003;289:2560-2572.